Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
作者信息
Vaughan Sarrazin Mary S, Jones Michael, Mazur Alexander, Cram Peter, Ayyagari Padmaja, Chrischilles Elizabeth
出版信息
J Am Coll Cardiol. 2017 Jan 24;69(3):360-362. doi: 10.1016/j.jacc.2016.11.023.
Abstract
摘要
相似文献
1
Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
J Am Coll Cardiol. 2017 Jan 24;69(3):360-362. doi: 10.1016/j.jacc.2016.11.023.
2
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
J Thromb Thrombolysis. 2019 Aug;48(2):240-249. doi: 10.1007/s11239-019-01838-5.
3
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.
Am Heart J. 2021 Mar;233:109-121. doi: 10.1016/j.ahj.2020.12.010. Epub 2021 Jan 14.
4
Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.
J Comp Eff Res. 2018 Jul;7(7):685-691. doi: 10.2217/cer-2017-0081. Epub 2018 May 29.
5
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
JAMA Cardiol. 2017 Aug 1;2(8):872-881. doi: 10.1001/jamacardio.2017.1883.
6
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
Expert Rev Pharmacoecon Outcomes Res. 2019 Apr;19(2):203-212. doi: 10.1080/14737167.2019.1527220. Epub 2018 Oct 4.
7
[Not Available].
Lakartidningen. 2018 Dec 4;115:FAXZ.
8
Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
Curr Cardiol Rep. 2015 Aug;17(8):61. doi: 10.1007/s11886-015-0618-4.
9
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.
10
Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.
Am J Cardiol. 2022 Feb 1;164:141-143. doi: 10.1016/j.amjcard.2021.10.018. Epub 2021 Nov 27.
引用本文的文献
1
The role of personalized atrial modeling in understanding atrial fibrillation mechanisms and improving treatment.
Int J Cardiol. 2019 Jul 15;287:139-147. doi: 10.1016/j.ijcard.2019.01.096. Epub 2019 Jan 31.
2
Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
BMC Cardiovasc Disord. 2018 Jan 25;18(1):11. doi: 10.1186/s12872-018-0746-z.
本文引用的文献
1
Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.
JAMA Intern Med. 2015 Jul;175(7):1245-7. doi: 10.1001/jamainternmed.2015.1299.
2
Matching by propensity score in cohort studies with three treatment groups.
Epidemiology. 2013 May;24(3):401-9. doi: 10.1097/EDE.0b013e318289dedf.
3
Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry.
J Cardiovasc Electrophysiol. 2007 Jun;18(6):628-33. doi: 10.1111/j.1540-8167.2007.00819.x. Epub 2007 Apr 19.
4
Comparisons of two-part models with competitors.
Stat Med. 2001 Apr 30;20(8):1215-34. doi: 10.1002/sim.790.
Zotero 插件